Data Bridge Market Research analyses that the pelvic cellulitis treatment market was valued at USD 378.91 million in 2021 and is expected to reach USD 530.65 million by 2029, registering a CAGR of 4.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample PDF of the report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo...

In recent years, the pelvic cellulitis treatment market is anticipated to grow rapidly during the forecast period. Although the majority of patients arrive with abdominal symptoms or sepsis symptoms, intra-abdominal abscesses have a wide range of clinical presentations. Consistent stomach pain/tenderness, distention, mass, or ileus are all possible symptoms. Also prevalent are nausea, anorexia, and weight loss. Pelvic cellulitis are inflammatory, fluid-filled lumps that can develop in the female pelvic. Bacteria infiltrate the upper vaginal canal, causing abscesses. The bacteria usually comes from a different genital tract illness, such as pelvic inflammatory disease (PID), or germs from the lower genital tract that have made their way up through the cervix. Pelvic cellulitis in males are extremely uncommon, and when they do occur, they usually grow above the prostate. They are more common in women. All these factor led to the high demand of pelvic cellulitis treatment in the market.

Some of the major players operating in the pelvic cellulitis treatment market are:

Allergan (Ireland)

Merck & Co., Inc. (US)

Sumitomo Corporation (Japan)

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Melinta Therapeutics LLC (US)

Basilea Pharmaceutica Ltd. (Switzerland)

Tetraphase Pharmaceuticals (US)

Paratek Pharmaceuticals, Inc. (US)

Nabriva Therapeutics plc (Ireland)

Spero Therapeutics (US)

Abbott (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (US)

Teva Pharmaceutical Industries Ltd.(Jerusalem)

Sanofi (France)

Novartis AG (Switzerland)

Sun Pharmaceutical Industries Ltd. (Mumbai)

Aurobindo Pharma (Hyderabad)

Lupin (Mumbai)

SHIONOGI & Co., Ltd. (Japan)

AbbVie Inc. (US)

Cumberland Pharmaceuticals Inc. (US)

Otsuka America Pharmaceutical, Inc. (US)

Eli Lilly and Company (US)

Market Definition

Pelvic cellulitis is commonly known as pelvic abscess. The most common causes of pelvic cellulitis include acute appendicitis, gynaecological diseases, and surgeries. It can also happen as a side effect of Crohn’s illness, diverticulitis, or abdominal surgery. An abscess is a collection of infected pus or fluid that is enclosed by inflammatory tissue. A pelvic abscess can grow fairly large before becoming ill or showing visible symptoms, making it easy to detect. The abscess is usually treated with antibiotics as well as draining the abscess. Antibiotics alone can be beneficial in the early stages of a minor abscess.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-pelvic-cell...

Pelvic Cellulitis Treatment Market Dynamics

Drivers

Increasing prevalence of pelvic inflammatory disease (PID)

The pelvic cellulitis treatment market is driven by an increase in prevalence of pelvic inflammatory disease (PID).

Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of pelvic cellulitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the pelvic cellulitis treatment market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of pelvic cellulitis treatment market. Along with this, rising geriatric population and changing lifestyle of people will enhance the growth rate of the market.

Opportunities

Increase in the number of research and development activities

Moreover, the market’s growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pelvic cellulitis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pelvic cellulitis treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of pelvic cellulitis treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pelvic cellulitis treatment market. Additionally, lack of awareness and strict regulatory framework that delays the approval of products will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This pelvic cellulitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pelvic cellulitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Browse the complete table of contents at – https://www.databridgemarketresearch.com/toc/?dbmr=global-pelvic-ce...

COVID-19 Impact on Pelvic Cellulitis Treatment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of pelvic cellulitis treatment in recent months.

Recent Development

In July 2020, Endo International plc had announced the launch of Qwo (collagenase clostridium histolyticum-aaes) with U.S. Food and Drug Administration (FDA) approval. QWO is a type of prescription drug that is used for the treatment of moderate to severe cellulite in the buttocks of adult women.

Global Pelvic Cellulitis Treatment Market Scope

The pelvic cellulitis treatment market is segmented on the basis of diagnosis, treatment, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

Ultrasound

Laparoscopy

CT scan

Endoscopic Ultrasound

Others

On the basis of diagnosis, the pelvic cellulitis treatment market is segmented into ultrasound, laparoscopy, CT scan, endoscopic ultrasound and others.

Treatment

Antibiotics

Others

On the basis of treatment, the pelvic cellulitis treatment market is segmented into antibiotics and others.

Dosage

Tablet

Injection

Others

On the basis of dosage, the pelvic cellulitis treatment market is segmented into tablet, injection and others.

Route of Administration

Oral

Intravenous

Others

The route of administration segment for the pelvic cellulitis market is segmented into oral, intravenous and others.

End-Users

Hospitals

Specialty Clinics

Homecare

Others

On the basis of end-users, the pelvic cellulitis treatment market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

On the basis of distribution channel, the pelvic cellulitis treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others

Report Coverage:
The report offers:
Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
Comprehensive insights into the regional developments.
List of major industry players.
Key strategies adopted by the market players.